RPG Life Sciences Q1 Results: Net Profit Rises 16% YoY To ₹305.7 Lakh

RPG Life Sciences reported a 16% year-on-year increase in standalone net profit to ₹305.7 lakh for the quarter ended June 30, 2026, driven by an 18.5% surge in revenue from operations. Consolidated net profit rose 17% to ₹307.6 lakh, reflecting consistent operational performance across its pharmaceutical segment. The results were approved by the Board of Directors at a meeting held on July 28, 2026, and reviewed by statutory auditors S R B C & Co LLP under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Revenue from operations grew to ₹195.69 crore in Q1FY26, up from ₹168.92 crore in the corresponding quarter of FY25. Total income stood at ₹199.85 crore on a standalone basis and ₹200.39 crore on a consolidated basis. The company operates in a single reportable business segment: Pharmaceuticals. Earnings per share (basic) increased to ₹18.49 from ₹15.90 in Q1FY25, while diluted EPS remained identical to basic figures.

Financial Performance

Metric	Standalone (₹ in Lakhs)	Consolidated (₹ in Lakhs)
Revenue from Operations	19,569	19,569
Total Income	19,985	20,039
Total Expenses	15,864	15,893
Profit Before Tax	4,121	4,146
Net Profit	3,057	3,076

Total expenses rose to ₹158.64 crore (standalone) and ₹158.93 crore (consolidated), primarily due to higher purchases of stock-in-trade and employee benefits expense. Finance costs remained minimal at ₹6.3 lakh. Income tax expenses were recorded at ₹10.64 crore (standalone) and ₹10.70 crore (consolidated).

Strategic Developments

The Board approved the transfer of its API division to wholly owned subsidiary RPG Active Pharma Limited, incorporated on December 24, 2025. This transaction, approved on December 15, 2025, is subject to requisite regulatory consents and customary conditions precedent. The company continues to monitor the impact of New Labour Codes notified effective November 22, 2025, which resulted in exceptional expenses of ₹116.9 lakh during FY26 due to changes in wage definitions.

What the Numbers Show

The divergence between revenue growth (18.5%) and net profit growth (16%) suggests modest margin compression, likely influenced by higher input costs and labor-related expenses. However, the absence of exceptional items in Q1FY26—unlike FY26 which included insurance claim settlements and impairment charges—indicates that core operational profitability has strengthened independently of one-off gains. The stable finance costs and controlled tax outlays further support sustainable earnings quality.

1 Day	5 Days	1 Month	6 Months	1 Year	5 Years
-0.57%	-4.20%	+26.06%	+46.36%	+27.93%	+492.86%

RPG Life Sciences Limited has announced the cessation of Ms. Zahabiya Khorakiwala as an Independent Director, effective July 26, 2026. The departure marks the conclusion of her second consecutive five-year term on the Board. This change triggers a reconstitution of the Sustainability and Corporate Social Responsibility Committee, altering the governance structure for environmental and social oversight within the company.

The disclosure was made pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The filing also references compliance with SEBI Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026. Rajesh Shirambekar, Head – Legal & Company Secretary, signed the disclosure submitted to both the National Stock Exchange of India Limited and BSE Limited on July 27, 2026.

Committee Reconstitution

Following Ms. Khorakiwala’s exit, she ceased to be a member of the Sustainability and Corporate Social Responsibility Committee. The Board reconstituted this committee effective July 27, 2026. The new composition places Ms. Radhika Gupta in the leadership role, with Mr. Sachin Nandgaonkar and Mr. Ashok Nair serving as members.

Name	Role
Ms. Radhika Gupta	Chairperson
Mr. Sachin Nandgaonkar	Member
Mr. Ashok Nair	Member

Director Details

Ms. Zahabiya Khorakiwala, identified by DIN 00102689, served her full term without incident or early resignation. The company confirmed that the reason for the change in directorship was strictly the completion of the statutory maximum tenure for independent directors under current regulations.

What the Numbers Show

The exit of an independent director after two consecutive terms is a standard regulatory requirement designed to ensure fresh perspectives on corporate governance boards. For RPG Life Sciences, this transition ensures compliance with SEBI’s norms on board rotation while maintaining continuity through the immediate reconstitution of key committees. The appointment of Ms. Radhika Gupta as Chairperson of the Sustainability and Corporate Social Responsibility Committee signals the company’s continued focus on ESG governance structures despite the personnel change.